These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38902559)

  • 1. Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies.
    Ikeda D; Isezaki T; Narita K; Yuyama S; Oura M; Uehara A; Tabata R; Takeuchi M; Matsue K
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):397-406. PubMed ID: 38902559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
    Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
    J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
    Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
    J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
    Kobayashi S; Yasu T; Momo K; Ohno N
    Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study.
    Tentoni N; Hwang M; Villanueva G; Combs R; Lowe J; Ramsey LB; Taylor ZL; Carrillo TM; Aumente MD; López-Viñau López T; Rizzari C; Howard SC
    Cancer Med; 2024 Sep; 13(17):e70176. PubMed ID: 39254047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
    Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
    Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
    Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning.
    Zhan M; Chen Z; Ding C; Qu Q; Wang G; Liu S; Wen F
    Int J Hematol; 2021 Oct; 114(4):483-493. PubMed ID: 34170480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
    Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
    Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
    Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
    Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for high-dose methotrexate-induced nephrotoxicity.
    Kawaguchi S; Fujiwara SI; Murahashi R; Nakashima H; Matsuoka S; Ikeda T; Toda Y; Ito S; Ban T; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Kanda Y
    Int J Hematol; 2021 Jul; 114(1):79-84. PubMed ID: 33743109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
    Taylor ZL; Mizuno T; Punt NC; Baskaran B; Navarro Sainz A; Shuman W; Felicelli N; Vinks AA; Heldrup J; Ramsey LB
    Clin Pharmacol Ther; 2020 Sep; 108(3):635-643. PubMed ID: 32558929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.
    May J; Carson KR; Butler S; Liu W; Bartlett NL; Wagner-Johnston ND
    Leuk Lymphoma; 2014 Jun; 55(6):1345-9. PubMed ID: 24004183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
    Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
    Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.